Dimensional Fund Advisors LP Sells 72,840 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Dimensional Fund Advisors LP lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 975,814 shares of the specialty pharmaceutical company's stock after selling 72,840 shares during the quarter. Dimensional Fund Advisors LP owned 3.03% of Collegium Pharmaceutical worth $27,957,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Invesco Ltd. boosted its stake in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the period. Renaissance Technologies LLC increased its position in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock worth $47,603,000 after buying an additional 5,480 shares during the last quarter. Royce & Associates LP raised its stake in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after buying an additional 33,674 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after acquiring an additional 175,892 shares during the period.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Colleen Tupper sold 10,445 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on COLL. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler restated a "neutral" rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday. Finally, StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded up $1.62 during trading hours on Friday, reaching $28.89. 561,658 shares of the stock traded hands, compared to its average volume of 436,387. The company's 50-day simple moving average is $28.10 and its two-hundred day simple moving average is $30.03. The company has a market capitalization of $928.29 million, a P/E ratio of 12.45 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.